Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus.
Fischer WA 2nd, Eron JJ Jr, Holman W, Cohen MS, Fang L, Szewczyk LJ, Sheahan TP, Baric R, Mollan KR, Wolfe CR, Duke ER, Azizad MM, Borroto-Esoda K, Wohl DA, Coombs RW, James Loftis A, Alabanza P, Lipansky F, Painter WP. Fischer WA 2nd, et al. Among authors: borroto esoda k. Sci Transl Med. 2022 Jan 19;14(628):eabl7430. doi: 10.1126/scitranslmed.abl7430. Epub 2022 Jan 19. Sci Transl Med. 2022. PMID: 34941423 Free PMC article. Clinical Trial.
Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306).
Sobel R, Nyirjesy P, Ghannoum MA, Delchev DA, Azie NE, Angulo D, Harriott IA, Borroto-Esoda K, Sobel JD. Sobel R, et al. Among authors: borroto esoda k. BJOG. 2022 Feb;129(3):412-420. doi: 10.1111/1471-0528.16972. Epub 2021 Nov 8. BJOG. 2022. PMID: 34676663 Free PMC article. Clinical Trial.
Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303).
Schwebke JR, Sobel R, Gersten JK, Sussman SA, Lederman SN, Jacobs MA, Chappell BT, Weinstein DL, Moffett AH, Azie NE, Angulo DA, Harriott IA, Borroto-Esoda K, Ghannoum MA, Nyirjesy P, Sobel JD. Schwebke JR, et al. Among authors: borroto esoda k. Clin Infect Dis. 2022 Jun 10;74(11):1979-1985. doi: 10.1093/cid/ciab750. Clin Infect Dis. 2022. PMID: 34467969 Free PMC article. Clinical Trial.
Ibrexafungerp is efficacious in a neutropenic murine model of pulmonary mucormycosis as monotherapy and combined with liposomal amphotericin B.
Gebremariam T, Alkhazraji S, Gu Y, Najvar LK, Borroto-Esoda K, Patterson TF, Filler SG, Wiederhold NP, Ibrahim AS. Gebremariam T, et al. Among authors: borroto esoda k. Antimicrob Agents Chemother. 2024 May 2;68(5):e0154523. doi: 10.1128/aac.01545-23. Epub 2024 Apr 1. Antimicrob Agents Chemother. 2024. PMID: 38557112
In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study.
Quindós G, Miranda-Cadena K, San-Millán R, Borroto-Esoda K, Cantón E, Linares-Sicilia MJ, Hamprecht A, Montesinos I, Tortorano AM, Prigitano A, Vidal-García M, Marcos-Arias C, Guridi A, Sanchez-Reus F, Machuca-Bárcena J, Rodríguez-Iglesias MA, Martín-Mazuelos E, Castro-Méndez C, López-Soria L, Ruiz-Gaitán A, Fernandez-Rivero M, Lorenzo D, Capilla J, Rezusta A, Pemán J, Guarro J, Pereira J, Pais C, Romeo O, Ezpeleta G, Jauregizar N, Angulo D, Eraso E. Quindós G, et al. Among authors: borroto esoda k. Front Cell Infect Microbiol. 2022 May 16;12:906563. doi: 10.3389/fcimb.2022.906563. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35651755 Free PMC article.
Anti-staphylococcal lysin, LSVT-1701, activity: In vitro susceptibility of Staphylococcus aureus and coagulase-negative staphylococci (CoNS) clinical isolates from around the world collected from 2002 to 2019.
Huang DB, Sader HS, Rhomberg PR, Gaukel E, Borroto-Esoda K. Huang DB, et al. Among authors: borroto esoda k. Diagn Microbiol Infect Dis. 2021 Nov;101(3):115471. doi: 10.1016/j.diagmicrobio.2021.115471. Epub 2021 Jun 26. Diagn Microbiol Infect Dis. 2021. PMID: 34280671
Molnupiravir, an Oral Antiviral Treatment for COVID-19.
Fischer W, Eron JJ, Holman W, Cohen MS, Fang L, Szewczyk LJ, Sheahan TP, Baric R, Mollan KR, Wolfe CR, Duke ER, Azizad MM, Borroto-Esoda K, Wohl DA, Loftis AJ, Alabanza P, Lipansky F, Painter WP. Fischer W, et al. Among authors: borroto esoda k. medRxiv [Preprint]. 2021 Jun 17:2021.06.17.21258639. doi: 10.1101/2021.06.17.21258639. medRxiv. 2021. PMID: 34159342 Free PMC article. Updated. Preprint.
Efficacy of Antistaphylococcal Lysin LSVT-1701 in Combination with Daptomycin in Experimental Left-Sided Infective Endocarditis Due to Methicillin-Resistant Staphylococcus aureus.
Huang DB, Gaukel E, Kerzee N, Borroto-Esoda K, Lowry S, Xiong YQ, Abdelhady W, Bayer AS. Huang DB, et al. Among authors: borroto esoda k. Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0050821. doi: 10.1128/AAC.00508-21. Epub 2021 Jul 16. Antimicrob Agents Chemother. 2021. PMID: 34097491 Free PMC article.
70 results